Efficacy of Dupilumab for Treatment of Moderate-to-Severe Asthma

Q4 Medicine

Clinical Pulmonary Medicine Pub Date : 2019-03-01 DOI:10.1097/CPM.0000000000000302

A. Pronko, D. Zappetti

引用次数: 0

Abstract

Synopsis: Dupilumab is a novel biologic agent that targets the shared interleukin 4/13 receptor. It is safe and efficacious in patients with moderateto-severe asthma; however, subgroup analysis suggests that patients with elevated markers of type-2 inflammation benefit most from this drug. Source: Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. NEJM 2018;378: 2486–2496.

查看原文本刊更多论文

Dupilumab治疗中重度哮喘的疗效

简介：Dupilumab是一种靶向共有的白细胞介素4/13受体的新型生物制剂。它对中重度哮喘患者是安全有效的；然而，亚组分析表明，2型炎症标志物升高的患者从该药物中获益最多。资料来源：Castro M，Corren J，Pavord ID等。Dupilumab治疗中重度未控制哮喘的疗效和安全性。NEJM 2018；378:2486-2496。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Pulmonary Medicine Medicine-Critical Care and Intensive Care Medicine

自引率

0.00%

发文量

期刊介绍： Clinical Pulmonary Medicine provides a forum for the discussion of important new knowledge in the field of pulmonary medicine that is of interest and relevance to the practitioner. This goal is achieved through mini-reviews on focused sub-specialty topics in areas covered within the journal. These areas include: Obstructive Airways Disease; Respiratory Infections; Interstitial, Inflammatory, and Occupational Diseases; Clinical Practice Management; Critical Care/Respiratory Care; Colleagues in Respiratory Medicine; and Topics in Respiratory Medicine.